<DOC>
	<DOC>NCT02554240</DOC>
	<brief_summary>This Phase II clinical study is to evaluate the efficacy and safety of DA-5202 in patients with osteoarthritis of the knee.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of Intra-articular DA-5202 in Patients With Osteoarthritis of the Knee</brief_title>
	<detailed_description>Eligible subjects are randomly assigned to receive DA-5202 high dose(20mg) or DA-5202 low dose(10mg) or Na Hyaluronate once a week intra-articular injection for 3 weeks.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<criteria>male and female patients between 20 and 80 y old primary knee osteoarthritis confirmed clinically and radiologically according to American College of Rheumatology criteria and have following 3 items 1. knee joint pain 2. have any of the following 1. males and females more than 50 y 2. morning stiffness within 30 minutes 3. crepitus 3. presence of spur on radiological evidence KellgrenLawrence Grade Ⅰ to Ⅲ confirmed radiologically knee pain under weightbearing greater than 40/100mmVAS(Visual Analogue Scale) at randomization visit patients willing and able to provide signed informed consent after the nature of the study has been explained BMI(Body Mass Index) &gt; 32 complete obliteration of femoropatellar joint space on Xray KellgrenLawrence Grade IV knee surgery within a year history of fracture, rheumatoid arthritis or other inflammatory arthritis in knee articular cavity intraarticular corticosteroid injection within 3 months or hyaluronate injection within 6 months skin diseases or infection overlying the joint history of severe drug allergy or hypersensitivity to drugs(piroxicam, hyaluronic acid) history of allergy, asthma, rhinitis, angioedema, rash to aspirin or other NSAIDs (including COX2 inhibitor) treatment with anticoagulants such as heparin or coumarins (warfarin etc.) History of GI diseases such as peptic ulcer, bleeding, perforation, ulcerative colitis, Crohn's disease within 1 year severe hypertension patients with psychiatric disorder, alcoholism, drug addiction presence of severe concomitant diseases or malignancy within 5 years have participated in another clinical trial 4 weeks prior to the study women of childbearing potential who are not using *adequate means of contraception (*adequate means of contraception: condom, oral contraception, barrier methods using spermicide, intrauterine devices etc.) any condition that, in the view of the investigator, would interfere with study participation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>